|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Leuk/Lymph Evaluation Panel 35080X
MessageTest Code
Alias/See Also
CPT Codes
88184; 88185 X 21; 88189
Includes
Additional markers may be performed based on the pathologist review. These markers will be performed at an additional charge (CPT code(s): 88185 for each additional marker).
Preferred Specimen
Bone marrow: 3 mL collected in a sodium heparin (green-top) tube, ACD-A (yellow-top) tube,or EDTA (lavender-top) tube or
Tissue or body fluids: Any type is acceptable
Minimum Volume
Other Acceptable Specimens
Instructions
Transport Container
Transport Temperature
Specimen Stability
Room temperature: 72 hours (may extend to 5 days, depending on cell viability)
Refrigerated: Not established
Frozen: Not established
Tissue and body fluids
Room temperature: Not established
Refrigerated: 72 hours
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Flow Cytometry (FC)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Reference Range
Clinical Significance
This panel may be used in the initial evaluation of patients with clinical suspicion of hematologic neoplasms. Immunophenotyping by flow cytometry can aid in the diagnosis and classification of leukemia and lymphoma [1]. Subsequent testing of additional cell surface antigens may be needed to help establish a diagnosis.
Leukemias and lymphomas are heterogenous morphologically and clinically. Identification of cell surface markers (T cell, B cell, progenitor, and myeloid markers) by flow cytometry can help assign a cell lineage to neoplastic cells. Accurate immunotyping aids in the diagnosis, classification, and prognosis of hematologic neoplasm and may inform treatment decisions [1].
This immunotyping panel is designed to expedite the evaluation of patients without provisional diagnosis of a certain type of hematologic neoplasm. The results of this panel must be interpreted with cytological, histological, genetic, and clinical findings to generate accurate diagnosis. Additional cell surface markers not included in this panel may be needed to evaluate certain hematologic malignancies (eg, hairy cell leukemia).
Because non-viable cells lead to non-specific antibody binding, specimens should be processed as early as possible.
The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.
Reference
1. Bain BJ, et al. Leukaemia Diagnosis. 5th ed. John Wiley & Sons;2017:69-134.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153